Apollo Cancer Centres launches Shield™ Multi-Cancer Detection, a blood-based test that can detect signs of multiple cancers ...

Five hospitals in England and Wales have switched to urine test, rather than invasive hospital procedure ...

Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ...

Nearly four in 10 women were initially told they had a UTI before later being diagnosed with bladder cancer. The post Bladder ...

Zydus and Apollo Hospitals collaborate to enhance access to a multi-cancer blood test for early detection in India.

Once an older man’s disease, worrying trend sees rates double in younger men.

The guidelines state that a test must be FDA-approved, personalized, tumor-informed, multiplex, and use PCR-NGS for ctDNA.

Unlike conventional screening methods that typically target a single cancer, Shield MCD is designed to detect signals ...

Apollo Cancer Centres has partnered with Zydus Lifesciences to introduce Guardant Health's Shield Multi-Cancer Detection ...

India launches a single blood test screening for 10 cancers, improving early detection while complementing - not replacing - ...

Zydus Lifesciences Ltd. has entered into an exclusive agreement with precision oncology company Guardant Health to introduce ...

Bladder cancer is often mistaken for UTIs with a urologist outliningg a list of 'painless' symptoms you should never ignore.